Poster Presentation 38th Lorne Cancer Conference 2026

Advancing Plasma Proteomics: Olink, Nanoparticle Enrichment, and Soluble HLA Profiling for Precision Biomarker Discovery (#209)

Terry Lim 1 2 3 , Samantha Emery-Corbin 2 , Erwin Tanuwidjaya 1 2 3 , Joel R Steele 2 , Scott A Blundell 2 , Iresha Hanchapola 2 , Komagal K Sivaraman 2 , Haijian Zhang 2 , Nivedhitha Selvakumar 1 3 , Pouya Faridi 1 2 3 , Ralf B Schittenhelm 2
  1. Clinical Proteomics Node (CPN), School of Clinical Sciences, Clayton, Victoria
  2. Monash Proteomics and Metabolomics Platform, Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia
  3. Hudson Institute of Medical Research, Clayton, VIC, Australia

The Monash Proteomics & Metabolomics Platform (MPMP) offers state-of-the-art plasma proteomics technologies to support precision biomarker discovery and systems biology research. Plasma is an accessible and clinically relevant biofluid for biomarker discovery, but its extreme dynamic range in combination with low-abundant proteins presents a significant challenge for deep analysis. MPMP addresses these challenges through complementary high-sensitivity and deep-coverage workflows that probe distinct layers of the plasma proteome and immunopeptidome. These include Olink™ Target 96/48 panels, nanoparticle-based enrichment strategies (SEER™, Mag-Net , and Enrich™), neat plasma proteomics, and soluble HLA (sHLA) analysis. Together, these approaches enable comprehensive plasma profiling. 

MPMP plasma proteomics capabilities:

  • Olink™ Target 96/48 Panels: Multiplexed proximity extension assay (PEA) technology enabling sensitive and reproducible quantification of up to 92 proteins per panel from just 1 µL of plasma. These panels cover key biological themes — such as oncology, inflammation, immune response, and cardiovascular health — making them ideal for hypothesis-driven studies, cohort screening, and longitudinal monitoring.
  • Nanoparticle Enrichment (SEER™, Mag-Net and Enrich): Dynamic range compression workflows routinely identify >5,000 proteins from as low as 50 µL plasma, representing a 3–5x increase over conventional depletion workflows. This method revealed previously undetectable low-abundance proteins by mass spectrometry, supporting discovery-driven biomarker research.
  • Neat plasma: Direct LC-MS analysis of undepleted plasma for clinical studies from only 2 µL routinely identifying >1,000 proteins.
  • sHLA Enrichment: Immunoaffinity capture of circulating HLA complexes, yielding 1,200–4,000 unique immunopeptides from 100 µL–1 mL plasma, providing a unique view of systemic antigen presentation. This approach uncovered disease-specific immune signatures, highlighting its value for oncology, transplant immunology, and infectious disease research.

MPMP provides researchers with flexible, high-performance plasma proteomics workflows to suit different research goals — ranging from targeted quantification with Olink™, to deep unbiased discovery with SEER™, Mag-Net, and Enrich, to immune-focused profiling via sHLA enrichment. These complementary approaches empower investigators to design tailored pipelines that address specific biological questions and accelerate biomarker discovery.

If you are interested in applying these technologies in your research, please visit us at monash.edu/researchinfrastructure/mpmp.